Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Free Cash Flow (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Free Cash Flow for 11 consecutive years, with -$27.5 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow changed N/A to -$27.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$49.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$72.4 million for FY2025, 132.78% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$27.5 million at Crescent Biopharma, down from -$16.9 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$5.1 million in Q1 2025, with the low at -$27.5 million in Q4 2025.
  • Average Free Cash Flow over 5 years is -$12.4 million, with a median of -$12.2 million recorded in 2021.
  • The sharpest move saw Free Cash Flow crashed 302.71% in 2021, then soared 57.07% in 2023.
  • Over 5 years, Free Cash Flow stood at -$12.8 million in 2021, then soared by 38.23% to -$7.9 million in 2022, then increased by 3.74% to -$7.6 million in 2023, then crashed by 38.08% to -$10.5 million in 2024, then crashed by 161.89% to -$27.5 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$27.5 million, -$16.9 million, and -$5.1 million for Q4 2025, Q2 2025, and Q1 2025 respectively.